Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Maurizio Fava, M.D.

Co-Author

This page shows the publications co-authored by Maurizio Fava and Marlene Freeman.
Connection Strength

7.588
  1. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.895
  2. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.817
  3. Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials. J Clin Psychopharmacol. 2017 Apr; 37(2):176-181.
    View in: PubMed
    Score: 0.723
  4. Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant. Ann Clin Psychiatry. 2017 02; 29(1):28-34.
    View in: PubMed
    Score: 0.715
  5. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 10; 21(10):1372-80.
    View in: PubMed
    Score: 0.660
  6. Female reproductive life cycle and hormones: methodology to improve clinical trials. J Clin Psychiatry. 2013 Oct; 74(10):1018-21.
    View in: PubMed
    Score: 0.567
  7. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604.
    View in: PubMed
    Score: 0.226
  8. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depress Anxiety. 2020 05; 37(5):485-495.
    View in: PubMed
    Score: 0.223
  9. 180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectr. 2020 Apr; 25(2):313-314.
    View in: PubMed
    Score: 0.223
  10. 181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. CNS Spectr. 2020 Apr; 25(2):314-315.
    View in: PubMed
    Score: 0.223
  11. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.
    View in: PubMed
    Score: 0.220
  12. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 09 24; 80(6).
    View in: PubMed
    Score: 0.215
  13. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497.
    View in: PubMed
    Score: 0.202
  14. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.201
  15. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.187
  16. Does folic acid interfere with lamotrigine? Lancet Psychiatry. 2016 08; 3(8):704-705.
    View in: PubMed
    Score: 0.173
  17. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. Int Clin Psychopharmacol. 2016 Mar; 31(2):100-9.
    View in: PubMed
    Score: 0.168
  18. The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study. J Nerv Ment Dis. 2015 Oct; 203(10):762-8.
    View in: PubMed
    Score: 0.163
  19. THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. Depress Anxiety. 2015 Aug; 32(8):605-13.
    View in: PubMed
    Score: 0.160
  20. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010 Jun; 71(6):669-81.
    View in: PubMed
    Score: 0.113
  21. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
    View in: PubMed
    Score: 0.113
  22. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 Aug; 49:122-132.
    View in: PubMed
    Score: 0.060
  23. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. J Clin Psychiatry. 2020 12 01; 82(1).
    View in: PubMed
    Score: 0.058
  24. Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. Int Clin Psychopharmacol. 2020 11; 35(6):313-321.
    View in: PubMed
    Score: 0.058
  25. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. J Affect Disord. 2020 12 01; 277:478-485.
    View in: PubMed
    Score: 0.057
  26. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.053
  27. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.051
  28. Massachusetts General Hospital SAFER criteria for clinical trials and research. Harv Rev Psychiatry. 2013 Sep-Oct; 21(5):269-74.
    View in: PubMed
    Score: 0.035
  29. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. J Clin Psychiatry. 2011 Aug; 72(8):1152-4.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.